Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation.
Animals
CHO Cells
Cadherins
/ metabolism
Calcineurin Inhibitors
/ pharmacology
Cell Proliferation
/ drug effects
Cells, Cultured
Cricetinae
Cricetulus
Cyclosporine
/ pharmacology
Epithelial-Mesenchymal Transition
/ drug effects
Human Umbilical Vein Endothelial Cells
/ drug effects
Humans
Signal Transduction
/ drug effects
Tacrolimus
/ pharmacology
Tumor Necrosis Factor-alpha
/ pharmacology
Calcineurin inhibitors
Chronic allograft rejection
Endothelial cells
Endothelial-to-mesenchymal transition
Transplantation
Tumor necrosis factor
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
19 11 2019
19 11 2019
Historique:
received:
07
09
2019
accepted:
11
09
2019
pubmed:
23
9
2019
medline:
23
6
2020
entrez:
23
9
2019
Statut:
ppublish
Résumé
Calcineurin Inhibitors (CNIs) are routinely used for immunosuppression following solid organ transplantation. However, the prolonged use of these agents lead to organ fibrosis which limits their efficacy. CNIs induce TGFβ expression, which is reported to augment endothelial-to-mesenchymal transition (EndMT), but their role in this process is not known. In these studies, we find that the CNIs FK506 and cyclosporine (CsA) are potent to increase endothelial cell (EC) proliferation using established in vitro assays (P < 0.05). Furthermore, using phosphokinase arrays, we find that each CNI activates the MAPK and Akt/mTOR signaling pathways, and that pharmacological inhibition of each pathway targets CNI-induced proliferative responses (P < 0.001). EndMT was evaluated by FACS for N-cadherin and CD31 expression and by qPCR for the expression of α-smooth muscle actin, N-cadherin and Snail. We find that CNIs do not directly induce dedifferentiation, while TGFβ and hypoxia induce EndMT in small numbers of EC. In contrast, the treatment of EC with the inflammatory cytokine TNFα was potent to elicit an EndMT response, and its effects were most notably in EC following proliferation/doubling. Taken together, these observations suggest that CNIs elicit proliferative responses, which enhance EndMT in association with local inflammation. The clinical implications of these findings are that anti-proliferative therapeutics have high potential to target the initiation of this EndMT response.
Identifiants
pubmed: 31542230
pii: S0006-291X(19)31764-4
doi: 10.1016/j.bbrc.2019.09.043
pmc: PMC7119266
mid: NIHMS1543117
pii:
doi:
Substances chimiques
Cadherins
0
Calcineurin Inhibitors
0
Tumor Necrosis Factor-alpha
0
Cyclosporine
83HN0GTJ6D
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
667-673Subventions
Organisme : NIAID NIH HHS
ID : R01 AI092305
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007726
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Nat Med. 2010 Dec;16(12):1400-6
pubmed: 21102460
Front Immunol. 2012 Apr 02;3:54
pubmed: 22566935
Transplantation. 2007 Jun 27;83(12):1542-50
pubmed: 17589335
Ann Transplant. 2016 Dec 20;21:775-783
pubmed: 27994216
J Immunol. 1979 Aug;123(2):751-4
pubmed: 37274
Am J Transplant. 2011 Apr;11(4):693-7
pubmed: 21446974
Immunobiology. 2013 Apr;218(4):443-54
pubmed: 22739237
Am J Transplant. 2019 Sep;19(9):2434-2445
pubmed: 30836425
Nat Med. 2007 Aug;13(8):952-61
pubmed: 17660828
J Pathol. 2016 Feb;238(3):378-80
pubmed: 26446982
Circ Res. 2010 Aug 6;107(3):418-28
pubmed: 20522804
J Cell Sci. 1992 Oct;103 ( Pt 2):521-9
pubmed: 1478952
J Biol Chem. 2010 Aug 13;285(33):25196-202
pubmed: 20554520
Curr Opin Nephrol Hypertens. 2011 May;20(3):297-305
pubmed: 21422927
J Am Soc Nephrol. 2011 Jun;22(6):1024-9
pubmed: 21566051
J Am Coll Cardiol. 2019 Jan 22;73(2):190-209
pubmed: 30654892
Kidney Int. 1996 May;49(5):1297-303
pubmed: 8731094
FEBS Lett. 1995 Jan 23;358(2):109-12
pubmed: 7828718
Am J Pathol. 2011 Nov;179(5):2660-73
pubmed: 21945322
Nat Med. 2002 Feb;8(2):128-35
pubmed: 11821896
J Clin Invest. 2007 Dec;117(12):3774-85
pubmed: 18060031
J Cell Biol. 1974 Mar;60(3):673-84
pubmed: 4363161
Biochem J. 2011 Aug 1;437(3):515-20
pubmed: 21585337
J Am Soc Nephrol. 2016 Jan;27(1):324-32
pubmed: 25995444
Nephrol Dial Transplant. 2014 Apr;29(4):799-808
pubmed: 24463188
Am J Pathol. 2010 Jan;176(1):85-97
pubmed: 20008127
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Biol Chem. 2008 Oct 3;283(40):27230-8
pubmed: 18660502
J Clin Invest. 2003 Dec;112(11):1655-65
pubmed: 14660742
Ann N Y Acad Sci. 2005 Jun;1051:551-8
pubmed: 16126995